<DOC>
	<DOCNO>NCT00062699</DOCNO>
	<brief_summary>To evaluate survival benefit associate Zemplar therapy compare Calcijex treatment secondary hyperparathyroidism subject Stage V chronic kidney disease hemodialysis measure time death .</brief_summary>
	<brief_title>Evaluate Survival Benefits Zemplar Versus Calcijex Subjects w/ Stage V Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Stage V Chronic Kidney Disease Patients Hemodialysis require treatment secondary hyperparathyroidism vitamin D therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>